Serum sickness secondary to treatment with the murine - Human chimeric antibody IDEC-C2B8 (rituximab)

Arthritis and Rheumatism

Volumn 44, Issue 7, 2001, Pages 1717-1718

  D'Arcy, Christopher A ^a   Mannik, Mart ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG EFFECT; HUMAN; MALE; POLYNEUROPATHY; PRIORITY JOURNAL; SERUM SICKNESS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RODENTIA; SERUM SICKNESS;

EID: 0034940417     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C     Document Type: Article

References (6)

1. Human serum sickness: A prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure
2. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab
3. Antibodies to human myeloperoxidase in glomerular immune deposits of systemic lupus erythematosus
4. Anti-Fab' antibodies in human sera. I. A study of their distribution in health and disease
5. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
6. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma